Importantly, cell viability, colony formation, and migration assays confirmed that MARCH9 overexpression conferred higher sensitivity of CRC cells to the treatment of p65 inhibitors, suggesting that MARCH9 promoted CRC progression by activating p65. Here, MARCHF9 is linked to colorectal carcinoma.